DIADEM SpA

DIADEM SpA is a startup with a mission to improve understanding of the risk of Dementia and Alzheimer’s disease, enabling earlier decisions and better outcomes for patients. Founded in 2012 as a spin-off of University of Brescia (Italy), DIADEM aims to be the first blood-based prognostic test for early detection of dementia, focusing on Alzheimer’s Disease. The company has developed a unique and novel solution to address challenges in early, accurate, predictive, fast, non-invasive, and cost-effective diagnosis, ultimately leading to improved treatment and patient outcomes. DIADEM recently received a significant $2.50M grant investment on 07 September 2022 from the National Institute on Aging. The company is also preparing for a global product launch in 2021 and planning further clinical trials to validate its claims. DIADEM's innovative approach and strategic partnerships position it as a promising player in the neurodegenerative disease diagnostics market.